# Vir Biotechnology's elebsiran and tobevibart combination meets goals in first Phase 3 hepatitis D trial

- Published: 2026-11-10 10:36 UTC
- Section: Life & Health › Medicine
- Tags: hepatitis D treatment, Vir Biotechnology Phase 3, elebsiran tobevibart, chronic hepatitis D, hepatitis D clinical trial, Hepcludex, hepatitis B superinfection
- URL: https://realtech.media/news/rt-7620b2378b2b37bb15e28881_vir_biotechnology_s/

**In the first of three Phase 3 trials, 44% of patients on the two-drug regimen had the virus largely eliminated and a normalized liver enzyme at 48 weeks, versus none in the delayed-treatment group.**

![Vir Biotechnology's elebsiran and tobevibart combination meets goals in first Phase 3 hepatitis D trial](https://realtech.media/media/2026/11/2a0bc7ed768306b5.jpg)
*Seza A Gulec, Kenneth Pennington, Michael Hall and Yuman Fong, Wikimedia Commons, CC BY 2.0*

Vir Biotechnology reported that its experimental two-drug combination, elebsiran and tobevibart, met the main objective of the first of three Phase 3 trials in chronic hepatitis D, according to biopharmadive.com [1]. The company announced the result on Sunday. After 48 weeks, 44% of treated participants had largely undetectable virus and normalized levels of an important liver enzyme. In the delayed-treatment cohort, none achieved this result, according to Vir [1].

The regimen also met a key secondary endpoint that looked only at reduction of viral levels: 79% of treated patients had a treatment response, the company said [1].

## Trial timeline

Two additional Phase 3 trials are ongoing, and their data are expected early next year. If the results of all three studies are positive, they would support a regulatory submission in 2027 [1].

## Hepatitis D and the treatment landscape

Hepatitis D is a liver infection that occurs only in people who have already contracted the hepatitis B virus. A person can be infected with both viruses at the same time or develop a superinfection, when hepatitis D enters the body after hepatitis B. The latter is linked to long-term illness such as liver scarring and organ failure, according to the U.S. Centers for Disease Control and Prevention [1].

The condition is uncommon in the U.S. The World Health Organization believes it affects 5% of people with chronic hepatitis B infections worldwide [1].

Treatment options for chronic hepatitis D are limited. Earlier this year the U.S. Food and Drug Administration made Gilead Sciences' Hepcludex, a once-daily injection, the first approved treatment for chronic hepatitis D in the U.S. In September, a drug acquired by Mirum Pharmaceuticals succeeded in a Phase 3 trial [1].

Vir was initially formed to work on infectious diseases and in 2021 brought to market the COVID-19 antibody drug Xevudy. The company has since restructured and now works primarily on T-cell engagers for cancer. It kept preclinical HIV research and the pivotal-stage hepatitis D program [1].

## Sources

1. [biopharmadive.com](https://www.biopharmadive.com/news/vir-chronic-hepatitis-d-drug-results-elebsiran-tobevibart/874089)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-7620b2378b2b37bb15e28881_vir_biotechnology_s/